Qiagen NV (QGEN) Expected to Post Earnings of $0.36 Per Share

Equities analysts forecast that Qiagen NV (NYSE:QGEN) will announce earnings of $0.36 per share for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Qiagen’s earnings, with estimates ranging from $0.34 to $0.37. Qiagen reported earnings of $0.33 per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 9.1%. The firm is expected to report its next quarterly earnings report on Tuesday, July 30th.

On average, analysts expect that Qiagen will report full-year earnings of $1.46 per share for the current financial year, with EPS estimates ranging from $1.44 to $1.48. For the next fiscal year, analysts anticipate that the company will post earnings of $1.64 per share, with EPS estimates ranging from $1.60 to $1.67. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Qiagen.

Qiagen (NYSE:QGEN) last issued its quarterly earnings data on Monday, May 6th. The company reported $0.27 earnings per share for the quarter, beating analysts’ consensus estimates of $0.26 by $0.01. Qiagen had a net margin of 12.68% and a return on equity of 12.15%. The business had revenue of $348.70 million for the quarter, compared to analysts’ expectations of $351.68 million. During the same period in the previous year, the business earned $0.26 earnings per share. The company’s revenue was up 1.5% on a year-over-year basis.

Several brokerages have commented on QGEN. Zacks Investment Research cut shares of Qiagen from a “hold” rating to a “sell” rating in a research report on Monday, April 15th. Goldman Sachs Group reiterated a “buy” rating on shares of Qiagen in a research report on Tuesday. UBS Group began coverage on shares of Qiagen in a research report on Friday, March 15th. They issued a “neutral” rating and a $42.00 price target on the stock. Deutsche Bank reiterated a “buy” rating on shares of Qiagen in a research report on Tuesday, January 29th. Finally, Jefferies Financial Group reiterated a “neutral” rating on shares of Qiagen in a research report on Monday, January 21st. Six equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $41.71.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Morgan Stanley raised its holdings in Qiagen by 16.3% during the 3rd quarter. Morgan Stanley now owns 1,468,052 shares of the company’s stock worth $55,611,000 after buying an additional 205,698 shares during the period. D. E. Shaw & Co. Inc. grew its stake in Qiagen by 19.8% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 1,756,276 shares of the company’s stock valued at $60,489,000 after acquiring an additional 290,673 shares in the last quarter. Vanguard Group Inc grew its stake in Qiagen by 2.0% during the 3rd quarter. Vanguard Group Inc now owns 6,627,163 shares of the company’s stock valued at $251,037,000 after acquiring an additional 128,125 shares in the last quarter. First Bank & Trust grew its stake in Qiagen by 12.7% during the 4th quarter. First Bank & Trust now owns 5,552 shares of the company’s stock valued at $191,000 after acquiring an additional 624 shares in the last quarter. Finally, Oppenheimer Asset Management Inc. purchased a new position in Qiagen during the 4th quarter valued at about $118,000. Hedge funds and other institutional investors own 64.98% of the company’s stock.

Qiagen stock traded down $0.33 during midday trading on Thursday, hitting $36.26. The company’s stock had a trading volume of 751,197 shares, compared to its average volume of 1,288,579. The company has a current ratio of 2.22, a quick ratio of 2.05 and a debt-to-equity ratio of 0.63. Qiagen has a 12 month low of $32.33 and a 12 month high of $41.55. The stock has a market cap of $8.79 billion, a PE ratio of 27.06, a price-to-earnings-growth ratio of 2.18 and a beta of 0.88.

Qiagen Company Profile

QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions.

Recommended Story: What is a Real Estate Investment Trust (REIT)?

Get a free copy of the Zacks research report on Qiagen (QGEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Qiagen (NYSE:QGEN)

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.